Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis

Clicks: 13
ID: 333831
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #360 of 407 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 407 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: : Antibody-drug conjugates (ADCs) have reshaped breast cancer treatment, yet their efficacy and toxicity in older adults (≥65 years) remain poorly characterized. METHODS: : We searched PubMed, Ovid MEDLINE, and Embase (Elsevier) through November 17, 2025 for phase 2 or 3 randomized trials comparing ADCs versus non-ADC therapies in metastatic or early-stage breast cancer. The primary analysis assessed progression-free survival (PFS) in metastatic disease and invasive disease-free survival (IDFS) in early-stage disease, stratified by age (≥65 vs. <65 years), using pooled hazard ratios (pHRs). Age-by-treatment interaction was assessed using the ratio of HRs. Secondary outcomes included overall survival (OS) and grade ≥3 adverse events (AEs). RESULTS: Of 3,045 records identified, 20 trials (14 metastatic, 6 early-stage; 13,055 participants, 18% aged ≥65 years) met inclusion criteria. In metastatic trials, ADCs improved PFS in both older (pHR, 0.64; 95% CI, 0.51-0.79) and younger participants (pHR, 0.58; 95% CI, 0.51-0.66), with no significant age-by-treatment interaction (pooled ratio of HRs, 1.10; 95% CI, 0.91-1.33). ADCs also improved OS in the metastatic setting, though no trial reported age-stratified OS. In early-stage trials, only two reported age-stratified IDFS, with discordant results precluding pooled analysis. Grade ≥3 AEs were reported across all trials, but only three provided age-stratified data, and none stratified AEs jointly by treatment arm and age. CONCLUSION: ADC efficacy in metastatic breast cancer was similar across age groups, though data in early-stage disease were limited. Insufficient age- and treatment-stratified toxicity reporting precludes meaningful safety assessment of ADCs in older adults with breast cancer.
Reference Key
openalex_W7223464315 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Samuel Jacob Margolis, Tahmineh R. Kalbasi, Yuliya Zektser, Arman M. Niknafs, Joyce Cui, Marla D. Lipsyc-Sharf, Alexis Ann LeVee, Hope S. Rugo, Aditya Bardia, Mina S. Sedrak
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag399
URL
https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djag399/72452764/djag399.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.